User profiles for T Andre

Thierry André

Hôpital Saint Antoine
Verified email at aphp.fr
Cited by 59765

Participation in extracurricular activities in secondary school: What is known, what needs to be known?

A Holland, T Andre - Review of educational research, 1987 - journals.sagepub.com
The paper reviews literature relating to extracurricular participation and adolescent
development. Five areas are described: personal-social characteristics, academic achievement, …

Five insights from the global burden of disease study 2019

…, D Anderlini, JA Anderson, T Andrei, CL Andrei… - The Lancet, 2020 - thelancet.com
The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a
rules-based synthesis of the available evidence on levels and trends in health outcomes, a …

[HTML][HTML] MicroScale Thermophoresis: Interaction analysis and beyond

M Jerabek-Willemsen, T André, R Wanner… - Journal of Molecular …, 2014 - Elsevier
T-Jump and thermophoresis signals are highlighted. (B) Thermophoresis signal from experiments
equivalent to those shown in (A). Error bars = sd; n = 3. (C) T-… demonstrate that T-jump …

[HTML][HTML] Pembrolizumab in microsatellite-instability–high advanced colorectal cancer

T André, KK Shiu, TW Kim, BV Jensen… - … England Journal of …, 2020 - Mass Medical Soc
Background Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability–high
(MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy. The …

[HTML][HTML] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer

T André, C Boni, L Mounedji-Boudiaf… - … England Journal of …, 2004 - Mass Medical Soc
… The most important prognostic indicator of survival in early colon cancer is the stage of the
tumor (T, according to the tumor–node–metastasis [TNM] classification), determined by the …

[HTML][HTML] Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

…, GGH Amul, D Anderlini, CL Andrei, T Andrei… - The lancet, 2020 - thelancet.com
Background In an era of shifting global agendas and expanded emphasis on non-communicable
diseases and injuries along with communicable diseases, sound evidence on trends …

[HTML][HTML] Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

…, D Anderlini, JA Anderson, CL Andrei, T Andrei… - The lancet, 2020 - thelancet.com
Background Rigorous analysis of levels and trends in exposure to leading risk factors and
quantification of their effect on human health are important to identify where public health is …

[PDF][PDF] Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

T André, C Boni, M Navarro, J Tabernero, T Hickish… - J clin oncol, 2009 - academia.edu
Purpose Three-year disease-free survival (DFS) was significantly improved in patients who
had undergone resection with curative intent for stage II or III colon cancer who received …

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch …

T André, A De Gramont, D Vernerey… - Journal of Clinical …, 2015 - ascopubs.org
… Means and proportions were compared using the t test and χ 2 test (or Fisher exact test),
respectively. OS was calculated from the date of random assignment to the date of death as a …

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients …

…, AF Sobrero, M Ducreux, Y Hotko, T André… - Journal of clinical …, 2010 - ascopubs.org
Purpose Panitumumab is a fully human anti–epidermal growth factor receptor (EGFR)
monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory …